Printer Friendly
The Free Library
23,375,127 articles and books


Clinical pharmacology.

Why don't patients use medication as prescribed?

What does the term 'adherence' mean?

Adherence describes all aspects of how well or how poorly a patient follows a prescribed drug-dosing regimen or medical advice. Adherence is synonymous with the old term 'compliance', but is preferred as it is more patient centred (compliance implies following orders). Adherence to therapy remains a challenge regardless of the patient's age, illness and social background. Health care providers initiate therapeutic regimens on the assumption that patients will take all their pills at the right time. Adherence is better with acute than chronic medication and tends to wane over time in cases of chronic disease. Even in the ideal circumstances of a randomised clinical trial, adherence to chronic medication is seldom more than 80%.

Patterns of non-adherence

Three major patterns of non-adherence are recognised: non-acceptance (the patient never actually starts treatment), incomplete execution (extra or missed doses, including 'drug holidays'), and early discontinuation (early cessation of dosing that is not resumed). Adherence is not limited to the number of doses taken every day, but also includes taking the dose at the right time or dosing interval. The most commonly observed deviations are missed or delayed doses. Taking drug holidays--the sudden cessation and resumption of dosing--is a potentially hazardous adherence behaviour. Restarting medications such as anti-arrhythmics (e.g. encainide or flecainide) or peripheral vasodilators without re-titration has resulted in lethal pro-arrhythmia or hypotension, respectively.

The consequences of poor adherence range from personal disability (treatment failure, e.g. ineffective pain control) to a worldwide threat (e.g. emergence of multidrug-resistant tuberculosis), depending on the illness, pattern of non-adherence and acceptable limits of the dosing interval (the degree of 'forgiveness' in the dosing regimen).

Why are patients non-adherent?

Adherence is a complex human behaviour and is influenced by the patient's personal and social characteristics. Health care facilities and prescribers can be barriers to adherence. Some common barriers to adherence are listed in Table I. Note that socio-economic status (except homelessness) and level of education are not barriers to adherence.

In his book, Improving Medication Adherence--How to Talk With Patients About Their Medication, Shawn Shea suggests three considerations in the decision to take medication:

1. feeling that there is something wrong

2. feeling motivated to try to get help through the use of medication

3. believing that the advantages of taking the medication will, in the long run, outweigh the disadvantages.

In addition, he suggests that there are three different beliefs that determine if a patient will start or stay on a medication:

1. efficacy of the medication

2. cost of the medication

3. psychological meaning of the medication.

If the health care worker does not address the above issues, then it is unlikely that the patient will adhere to the prescribed treatment.

How can adherence be measured?

A major problem in assessing adherence, both for individual patient care and research, is that a gold standard for measuring adherence has not been identified. Direct and indirect methods are used to monitor adherence, each with advantages and disadvantages (Table II).

Directly observed therapy and measurement of drug concentrations (e.g. therapeutic drug monitoring) are considered direct methods of measuring adherence, but are expensive and provider intensive. Directly observed therapy has been promoted by national tuberculosis programmes, but recent studies indicate that more patient-centered approaches are more successful than traditional clinic-based directly observed therapy. 'White coat' adherence, the phenomenon whereby patients increase adherence a few days before or after a consultation, is common. If the patient is taking a drug that is suitable for therapeutic drug monitoring, white coat adherence can result in drug concentrations being in the therapeutic range, thus masking poor adherence. This is especially likely if the drug has a short half-life.

Methods to monitor adherence include self-report (asking patients about adherence or using questionnaires/medication diaries), caregiver/peer reports, assessing clinical response (e.g. correlating an outcome measure to adherence), pill counts, pharmacy refill rates, and electronic medication monitors (electronic monitors that record the date and time of opening pill bottles or actuating canisters).

How can adherence be improved?

One of the problems in addressing poor adherence is that it can be difficult to distinguish different types of adherence behaviour. For example, 50% adherence can mean either a patient who follows the dosing instructions meticulously but stops completely halfway into treatment because of intolerable side-effects, or a patient who only takes half the number of pills every day to try to save money. The interventions required to improve adherence will be completely different in these two examples.

Several adherence interventions and combinations of interventions have been studied. The type of intervention will depend on the barrier(s) to adherence. Informational interventions aim to increase the provision and retention of treatment-related information (e.g. structured individual or group counselling or education by physicians, health educators, and/or pharmacists). The most common and effective behavioural interventions are simplifying dose regimens, specialised packaging, and cognitive behaviour therapy. Informational and behavioural interventions are often combined.

Interventions that are simple and easy to implement in practice are:

* Always make a point of checking patients' adherence. Doctors often overestimate patients' reported medication use. Patients like to please health care providers, and will report what they expect the health care provider would like to hear.

* Asking patients in a reassuring and non-judgemental manner if it has been difficult for them to take all their medications, and asking what you can do to help them not to miss doses.

* Asking patients about side-effects; this can also often unmask poor adherence.

* It is important to make the patient feel part of the therapeutic decision-making process.

* Always follow-up adherence interventions and reassess the patient's commitment/interest in the treatment plan.

What is the take-home message?

Patients' adherence to a prescribed regimen or medical advice is a complex behaviour. A patient's engagement with his/her illness, the prescribed drug regimen, the health care providers and health care facilities can all act as barriers to acceptable levels of adherence. Health care providers usually overestimate patients' reported medication use. Monitor for poor adherence in asymptomatic diseases and when patients fail therapy despite an optimal dosing regimen.

C. Everett Koop, former Surgeon General of the USA, is accredited with the following excellent advice: 'Drug's don't work in patients who don't take them'.

Recommended reading

Diiorio C, McCarty F, Depadilla L, et al. Adherence to antiretroviral medication regimens: A test of a psychosocial model. AIDS Behaviour 3 November 2007 (Epub ahead of print).

Osterberg L, Blaschke, T. Adherence to medication. N Engl J Med 2005; 353: 487-497.

Shea SC. Improving Medication Adherence: How to Talk With Patients About Their Medications. Philadelphia: Lippincott Williams & Wilkins, 2006.

Simoni JM, Montgomery A, Martin E, New M, Demas AD, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007; 119(6): e1371-e1383. (Epub 28 May 2007, Review.)

Urquhart J, Vrijens B. Introduction to pharmionics: the vagaries in ambulatory patients' adherence to prescribed drug dosing regimens, and some of their clinical and economic consequences. In: Mann RD, Andrews EB, eds. Pharmacovigilance. Chichester: John Wiley & Sons Ltd, 2007: 603-618.

JAN-STEFAN VAN DER WALT, MB ChB

GARY MAARTENS, MB ChB, MMed, FCP

(SA), DTM&H

Division of Clinical Pharmacology, Department

of Medicine, University of Cape Town
Table I. Common barriers to adherence to treatment for chronic
conditions

Patient characteristics
 Adolescence
 Forgetfulness
 Running out of pills
 Missed clinic appointments
 Travelling
 Poor access to pharmacy
 Other priorities (including financial commitments)
 Lack of information
 Lack of belief in benefit of treatment
 Lack of insight into the illness
 Not counselled in home language
 Psychological problems
 Active depression
 Substance abuse
 Cognitive impairment
 Lack of self-efficacy (the belief that a patient can execute a
 behaviour required to produce a certain outcome successfully)

Treatment/disease characteristics

 Treatment of asymptomatic diseases
 Side-effects of medication
 Complexity of treatment (e.g. dosing frequency, number of pills,
 food restrictions)
 Treatment regimen incompatible with patient's lifestyle/routine

Prescriber characteristics

 Poor knowledge of drug costs/medical-aid coverage
 Low level of job dissatisfaction
 Prescribing complex regimen
 Prescribing a regimen incompatible with the patient's lifestyle
 Poor therapeutic relationship

Health care system

 Missed appointments
 High health care costs (costs of drugs, co-payments, or both)
 Inability of patient to access the pharmacy
 Switching to a different formulary

Table II. Advantages and disadvantages of direct
and indirect adherence methods

Method Advantages Disadvantages

Self-report Inexpensive Considerably
Caregiver report Allows discussion overestimates
(questioning of reasons for low adherence
patients adherence
directly,
and completing
questionnaires)

Clinical outcome Inexpensive Confounded by
(measuring drug Allows discussion factors other
effect, e.g. of reasons for low than non-adherence
[HbA.sub.1c] adherence
in diabetics,
lipid profiles
for patients on
statins, viral
loads for patients
on HAART)

Pharmacy refill Suitable for Moderately
(rates of individual patients overestimates
refilling as well as adherence
prescriptions) programmes (more sensitive
 than pill counts)

Pill count Inexpensive Patients rapidly
(counting the number Useful to detect learn to provide
of pills remaining misconceptions about the correct number
in the patient's dosing, especially of pills
medication bottles early on in therapy (discarding unused
or vials) doses/not returning
 unused medication)

 Time consuming

 Moderately
 overestimates
 adherence

Therapeutic Direct measure Expensive
drug monitoring Detection/prevention
(measuring drug of drug toxicity, Subject to 'white
and metabolite especially in coat' adherence
concentrations in populations at and may reflect
blood or urine) risk (e.g. elderly, only that the
 children, pregnancy, last dose
 renal or liver was taken
 impairment)
 Confounded by
 other causes
 of low
 concentrations

 May overestimate
 adherence

Electronic Provides data on Expensive
medication monitoring timing and
(electronic monitor patterns of Unable to detect
that records the date missed doses if patient
and time of opening takes wrong dose,
pill bottles, or takes multiple
actuating canisters, doses out of
etc.) container at the
 same time (e.g.
 taking morning
 and evening doses
 out simultaneously
 and putting the
 evening dose
 into a small
 pill box)

 May underestimate
 adherence
COPYRIGHT 2008 South African Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:Van der Walt, Jan-Stefan; Maartens, Gary
Publication:CME: Your SA Journal of CPD
Geographic Code:6SOUT
Date:Feb 1, 2008
Words:1653
Previous Article:Clinical hypnosis and psychoneuro-immunology: the body and mind are intimately linked, often completely subconsciously.
Next Article:Bare below the elbows.
Topics:



Related Articles
A web based course in clinical pharmacology.
ASCPT panel releases position statement on dietary supplement oversight.
Bioequivalence and statistics in clinical pharmacology.
Lecture notes; clinical pharmacology and therapeutics, 7th ed.
Medical webwatch.
PAREXEL EXPANDS RELATIONSHIP WITH SYNCHRON IN INDIA.
Instant clinical pharmacology, 2d ed.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters